Allurion Technologies Files S-1/A with Financial Updates

Ticker: ALURW · Form: S-1/A · Filed: Jan 8, 2025 · CIK: 1964979

Sentiment: neutral

Topics: filing, financials, restructuring

TL;DR

Allurion S-1/A filed Jan 8, 2025. Financials adjusted for reverse split & biz combo. Investors check this.

AI Summary

Allurion Technologies, Inc. filed an S-1/A on January 8, 2025, detailing its financial performance and business operations. The filing includes retrospective adjustments for a reverse stock split and business combination, impacting share calculations for periods prior to the combination. Allurion Technologies, Inc. is based in Natick, MA, and operates in the surgical and medical instruments sector.

Why It Matters

This filing provides updated financial information and operational details for Allurion Technologies, Inc., which is crucial for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: medium — S-1/A filings often indicate a company is preparing for significant corporate actions like an IPO or major financial restructuring, which inherently carry risks.

Key Numbers

Key Players & Entities

FAQ

What specific financial periods are covered by the retrospective adjustments mentioned in the filing?

The filing mentions retrospective adjustments for periods prior to the Business Combination and for all periods affected by the Reverse Stock Split, with specific dates like 2024-01-01 to 2024-09-30, 2023-12-31, and 2022-12-31 referenced.

What is the Standard Industrial Classification (SIC) code for Allurion Technologies, Inc. and what does it represent?

The SIC code is 3841, which corresponds to 'SURGICAL & MEDICAL INSTRUMENTS & APPARATUS'.

What was the former name of Allurion Technologies, Inc. and when did the name change occur?

The former name was ALLURION TECHNOLOGIES HOLDINGS, INC., and the name change occurred on February 7, 2023 (20230207).

What is the business address and phone number for Allurion Technologies, Inc. as listed in the filing?

The business address is 11 HURON DR STE 200, NATICK, MA 01760, and the business phone number is 508-647-4000.

What is the significance of the retrospective adjustments to weighted-average common shares and net loss per share?

These adjustments are made to reflect the equivalent number of shares outstanding immediately after the Business Combination and to give effect to the Reverse Stock Split, ensuring accurate per-share calculations for all periods.

Filing Stats: 4,463 words · 18 min read · ~15 pages · Grade level 17.5 · Accepted 2025-01-08 08:16:28

Key Financial Figures

Filing Documents

USE OF PROCEEDS

USE OF PROCEEDS 78 MARKET PRICE AND DIVIDEND INFORMATION 80 CAPITALIZATION 81

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 112 MANAGEMENT 139

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 150 DIRECTOR COMPENSATION 155 PRINCIPAL STOCKHOLDERS 157 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 159

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 165

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING 178 MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS 181 PLAN OF DISTRIBUTION 187 LEGAL MATTERS 190 EXPERTS 190 WHERE YOU CAN FIND MORE INFORMATION 190 INDEX TO FINANCIAL STATEMENTS F-1 i Table of Contents ABOUT THIS PROSPECTUS You should rely only on the information contained in this prospectus, any amendment or supplement to this prospectus, and any related free writing prospectus prepared by or on behalf of us or to which we have referred you. Neither we nor the placement agent have authorized anyone to provide you with information that is different from, or in addition to, that contained in this prospectus, any amendment or supplement to this prospectus and any related free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the placement agent take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is not an offer to sell, nor is it seeking an offer to buy, these securities in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of the securities offered hereby. Our business, financial condition, results of operations and prospects may have changed since that date. Neither we nor the placement agent have taken any action that would permit this offering, or possession or distribution of this prospectus, in any jurisdiction where action for that purpose is required, other than in the United States. Persons who have come into possession of this prospectus in a jurisdiction outside the United States are required to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus applicable to that jurisdiction. All reference

Forward-looking statements in this prospectus include, but are not limited to, statements about our ability to

Forward-looking statements in this prospectus include, but are not limited to, statements about our ability to: realize the benefits expected from the business combination (the "Business Combination") between Allurion and Compute Health Acquisition Corp. ("Compute Health") pursuant to that certain Business Combination Agreement, dated as of February 9, 2023 (as amended, the "Business Combination Agreement"), by and among Allurion, Legacy Allurion, Compute Health, Compute Health Corp., ("Merger Sub I") and Compute Health LLC ("Merger Sub II" and, together with Merger Sub I, the "Merger Subs"); successfully defend litigation that may be instituted by or against us; manage various conflicts of interest that could arise among us or our affiliates, investors, directors, and officers; successfully manage our cash and cash equivalents and any anticipated proceeds from this offering or the Chardan Equity Facility (as defined herein); maintain the listing of our securities on the NYSE, and the potential liquidity and trading of such securities; achieve the benefits of the collaboration with Medtronic plc ("Medtronic"); acquire sufficient sources of funding if and when needed; attract and retain key employees, officers, and directors; implement and achieve business plans, forecasts, and other expectations, including any financial projections provided to PIPE Investors (as defined herein) in connection with the Business Combination, the Purchasers in connection with the Notes (each as defined herein), and the investors in any offering hereunder, and identify and realize additional opportunities; manage risks associated with our management having limited experience operating as a public company; commercialize current and future products and services and create sufficient demand among health care providers and patients for such products, including the recent launch of our compounded GLP-1 program and achieving the expected benefits of such program; succes

View Full Filing

View this S-1/A filing on SEC EDGAR

View on Read The Filing